Oxford BioDynamics launches EpiSwitch oncology test

2021 01 12 23 44 3780 Blood Test Samples Lab 400

Oxford BioDynamics announced the clinical validation and U.S. launch of its EpiSwitch checkpoint inhibitor response test (CiRT) for oncology.

The blood test predicts the likelihood of a cancer patient's response to immune checkpoint inhibitors (ICIs), including anti-programmed cell death ligand 1 (anti-PD-L1) and anti-PD-1 immunotherapies. The test aims to enable doctors to make informed decisions on whether to recommend beginning or continuing treatment with an ICI. Also, it aims to allow clinicians to make a treatment decision without the need of a biopsy.

Page 1 of 164
Next Page